Amarin Corporation (AMRN) investor relations material

Executive summary

• Marked the one-year anniversary of a dual commercial strategy, combining U.S. operations with a fully partnered international platform, resulting in a scalable business model and a clearer path to sustainable growth and profitability.

• Achieved early success with a fully partnered international commercial strategy, driving global volume growth and reducing operating expenses.

• Maintained a leading U.S. market presence for IPE, with branded prescription growth and increased market share.

• Positive cash flow generated for the third consecutive quarter, with expectations for continued growth and profitability.

• Strong financial foundation with growing cash position and no debt supports commercial trends.

Financial highlights

• Q2 2026 net revenue was $42.2 million, down from $72.7 million in Q2 2025, which included a $25 million upfront payment from the Recordati transaction.

• Product revenue was $39.1 million, compared to $46.6 million in Q2 2025.

• U.S. product revenue declined to $32.2 million from $36.5 million year-over-year, reflecting ongoing pricing pressure but higher product volumes.

• European product revenue was $5.4 million, down 17% year-over-year, reflecting the transition to the partner model.

• Net loss improved to $7.7 million from $14.1 million year-over-year; net margin improved to -18%.

• Operating expenses dropped 59% to $27.0 million, reflecting the completion of a $70 million annual cost savings initiative.

• Cash and investments at quarter-end were $314.6 million, up from $303 million at year-end 2025, with no debt.

• Generated $7 million in positive cash flow from operations in Q2 2026, marking the third consecutive quarter of positive cash flow.

Outlook and guidance

• Provided outlook for key metrics for full year 2026, enabled by the new operating model and strong partnerships.

• Expect U.S. volumes to remain stable through the end of 2026, with exclusivity with key payers maintained through year-end.

• Expects continued international market growth, stable U.S. volumes, improved operating expense profile, and positive cash flow for full year 2026.

• Cash is projected to grow by approximately 10% by year-end 2026 compared to year-end 2025.